---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005383"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:09:10.492549+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aptose Q2 net loss $7.0M; cash $1.3M; CSRC okays TUS dose escalation to 160 mg

## Summary
- Net loss $7.0M ($2.76 per share) for Q2 2025, vs. $7.3M in Q2 2024; loss per share improved on higher share count.
- Cash and equivalents $1.3M as of June 30, 2025; company says cash insufficient to fund operations, relying on Hanmi loan of up to $8.5M.
- Safety Review Committee approved dose escalation of tuspetinib to 160 mg in TUS+VEN+AZA TUSCANY trial; 120 mg cohort all patients remain on study.
- All 10 enrolled subjects in TUSCANY triplet remain on treatment; CRs achieved at 40 mg and 80 mg doses across diverse AML mutations.
- Selected EY as new auditor; annual meeting reconvened for August 22, 2025 to vote on appointment.

## SEC filing metadata
- accession: 0001171843-25-005383
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325005383/0001171843-25-005383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325005383/f8k_081325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005383
- JSON: https://secwatch.observer/filing/0001171843-25-005383.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.